Can established onconeural antibodies persist after successful cancer treatment?

Established onconeural antibodies—particularly those directed at intracellular neuronal antigens—may remain detectable long after the associated cancer has been treated successfully. This matters because seropositivity can reflect a durable tumor-associated immune history rather than current cancer activity.

Clinical evidence

• Reviews and clinical reports indicate that classic onconeural antibodies can persist in serum and cerebrospinal fluid after cancer treatment and neurological recovery. A reported CV2/CRMP5-positive patient remained positive for years following small-cell lung cancer remission; an anti-Hu case remained seropositive through 3 years of complete remission.
• Persistence is variable: titers may decline, remain stable, or increase, and isolated anti-amphiphysin observations show marked post-treatment decreases. Across patients, serial titers correlate poorly with neurological trajectory.
• Accordingly, persistent antibody positivity alone does not establish tumor persistence/recurrence or active neurological disease. It should be interpreted alongside symptoms, examination, imaging, and standard phenotype- and antibody-directed cancer surveillance.

Mechanistic interpretation

• Persistence after removal of the apparent tumor antigen source makes a residual remote immune state biologically plausible. Potential explanations include durable immune memory and long-lived antibody-secreting plasma cells.
• For intracellular-antigen antibodies such as Hu and Yo, antibodies are generally markers of a predominantly T-cell-mediated antitumor/anti-neuronal immune response rather than direct mediators of neuronal injury. Thus, detectable antibody may signify a prior established immune response without demonstrating ongoing pathogenic immune activity.

Interpretation

• The evidence directly supports post-treatment antibody persistence, although longitudinal data are largely reviews, small heterogeneous series, and case reports rather than standardized prospective remission cohorts.
• Persistent seropositivity supports the possibility of remote immune priming after malignancy becomes inactive, but does not prove continued priming, occult cancer, or active paraneoplastic neurologic disease.

Bottom line

• Established onconeural antibodies can persist for months to years after successful cancer treatment; this is compatible with durable immune imprinting, but antibody detection alone is not evidence of cancer recurrence or ongoing neurologic injury.